tucaresol

Tucaresol is a substituted benzaldehyde and orally active small molecule that was originally developed for the prevention of sickle cell disease. Its mechanism involves interacting with hemoglobin to increase oxygen affinity, thereby inhibiting red blood cell sickling. Tucaresol also acts as an immunomodulator by enhancing co-stimulatory signaling to CD4+ T helper cells through transient covalent bonding (Schiff base formation) with surface amines on antigen-presenting cells and T-cells, mimicking natural immune activation processes. This results in increased type 1 cytokine production and improved antiviral immune responses. Tucaresol has demonstrated weak direct antiviral activity against several viruses (including HIV, hepatitis B virus, human herpesvirus 6B, measles virus, and human papillomavirus), but its primary effect appears to be host-targeted immune modulation rather than direct viral inhibition. It has been investigated in clinical trials for HIV infection (up to phase II), sickle cell disease, hepatitis B infection, leishmaniasis (preclinical/animal models), malignant melanoma (phase I/II), and more recently as a potential treatment for COVID-19 due to its ability to disrupt viral RNA synthesis and inhibit enzymes crucial for viral replication[1][3][4][5][6][7]. Development for most indications has been discontinued.

Other names

tucaresol4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid4-((2-formyl-3-hydroxyphenoxy)methyl)benzoic acid